Eziclen Drug Utilisation in Real Life Setting

Ipsen1,286 enrolled

Overview

The purpose of the study is to assess Eziclen/Izinova drug utilisation in the real life setting in a representative sample of the European target population.

Study Type

OBSERVATIONAL

Enrollment

1,286

Conditions

Bowel Cleansing

Interventions

Eziclen®/Izinova®DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient eligible for a prescription of BLI800 (Eziclen®/Izinova®) as a cleansing bowel preparation in accordance with the marketing authorisation. * Patient having provided written informed consent. Exclusion Criteria: * Patient not eligible for a prescription of BLI800 (Eziclen®/Izinova®) as a cleansing bowel preparation in accordance with the marketing authorisation. Specifically, patients in whom there is a contraindication for use of this product, including patients with congestive heart failure, severe renal insufficiency of active inflammatory bowel disease, are not eligible for inclusion in this study. * Patient being prescribed a cleansing bowel preparation other than BLI800 (Eziclen®/Izinova®).

Locations (16)

Ustredni vojenska nemocnice

Prague, Czechia

Krajská zdravotní, a.s., nemocnice Teplice

Teplice, Czechia

Outcomes

Primary Outcomes

Volume of liquid intake

Assessment of non-compliance in terms of insufficient liquid intake. The volume of water and clear liquids taken will be derived from the remaining volumes as recorded on the patient's leaflet and reported by the Investigator. Compliance to the hydration guidelines expressed in terms of a ratio (actual volume taken versus theoretical volume).

Time frame: on the day of the colonoscopy

Secondary Outcomes

Number of adverse events

Time frame: Up to 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.